Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06649751 in Parkinson's disease has completed and results were posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• PF-06649751 (PF-06649751)

Snippet

Sponsor: Pfizer | Conditions: Parkinson's Disease | Phase 1 | Status: COMPLETED | Results posted: 2017-03-27